Molecular imaging of pulmonary cancer and inflammation.
Molecular imaging (MI) may be defined as imaging in vivo using molecules that report on biologic function. This review will focus on the clinical use of radioactive tracers (nonpharmacologic amounts of compounds labeled with a radioactive substance) that permit external imaging using single photon emission computed tomography (planar, SPECT) or positron emission tomography (PET) imaging. Imaging of lung cancer has been revolutionized with the use of fluorine-18-labeled fluorodeoxyglucose (18F-FDG), an analog of glucose that can be imaged using PET. The ability to carry out whole body imaging after intravenous injection of 18F-FDG allows accurate staging of disease, helping to determine regional and distant nodal and other parenchymal involvement. Glycolysis is increased in nonmalignant conditions, including inflammation (e.g., sarcoidosis), and 18F-FDG PET is a sensitive method for evaluation of active inflammatory disease. Inflammatory disease has been imaged, even before the advent of PET, with planar and SPECT imaging using gallium-67, a radiometal that binds to transferrin. Metabolic alteration in pulmonary pathology is currently being studied, largely in lung cancer, primarily with PET, with a variety of other radiotracers. Prominent among these is thymidine; fluorine-18-labeled thymidine PET is being increasingly used to evaluate proliferation rate in lung and other cancers. This overview will focus on the clinical utility of 18F-FDG PET in the staging and therapy evaluation of lung cancer as well as in imaging of nonmalignant pulmonary conditions. PET and SPECT imaging with other radiotracers of interest will also be reviewed. Future directions in PET imaging of pulmonary pathophysiology will also be explored.
Divgi
Chaitanya R
CR
Nuclear Medicine Clinical Molecular Imaging, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. chaitanya.divgi@uphs.upenn.edu
D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis*; D057054:Molecular Imaging; D011014:Pneumonia / Q000175:diagnosis*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D015899:Tomography, Emission-Computed, Single-Photon
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
Nucl Med Biol. 2006 Nov;33(8):945-52
17127166
Cancer. 2008 Dec 1;113(11):3213-21
18924145
J Thorac Oncol. 2007 Oct;2(10):947-52
17909358
J Exp Clin Cancer Res. 2008 Oct 17;27:52
18928537
Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1537-43
18418595
Br J Cancer. 2008 May 20;98(10):1597-601
18475291
Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1298-306
19028270
Semin Nucl Med. 2008 Mar;38(2):137-40
18243849
J Nucl Med. 2008 Jan;49(1):22-9
18077538
Radiol Clin North Am. 2008 Mar;46(2):225-41, viii
18619378
J Natl Cancer Inst. 1991 Jan 16;83(2):97-104
1988695
Radiol Clin North Am. 2007 Jul;45(4):627-38, v
17706527
Semin Nucl Med. 2007 Nov;37(6):451-61
17920352
Cancer Control. 2008 Apr;15(2):112-9
18376378
J Nucl Med. 2008 Jun;49 Suppl 2:64S-80S
18523066
Semin Respir Infect. 1997 Jun;12(2):70-8
9195672
J Thorac Oncol. 2008 Feb;3(2):177-86
18303441
Proc Am Thorac Soc. 2005;2(6):541-4, 512
16352762